Lexeo Therapeutics, Common Stock Fundamentals
| LXEO Stock | 5.21 0.47 8.27% |
Lexeo Therapeutics, Common fundamentals help investors to digest information that contributes to Lexeo Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Lexeo Stock. The fundamental analysis module provides a way to measure Lexeo Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexeo Therapeutics, stock.
At this time, Lexeo Therapeutics,'s Net Interest Income is very stable compared to the past year. As of the 30th of January 2025, Depreciation And Amortization is likely to grow to about 2.2 M, while Interest Expense is likely to drop about 121.9 K. Lexeo | Select Account or Indicator |
Lexeo Therapeutics, Common Company Return On Asset Analysis
Lexeo Therapeutics,'s Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lexeo Therapeutics, Return On Asset | -0.4 |
Most of Lexeo Therapeutics,'s fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexeo Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Lexeo Total Assets
Total Assets |
|
Based on the latest financial disclosure, Lexeo Therapeutics, Common has a Return On Asset of -0.3993. This is 95.44% lower than that of the Biotechnology sector and 98.31% lower than that of the Health Care industry. The return on asset for all United States stocks is 185.21% higher than that of the company.
Lexeo Therapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lexeo Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Lexeo Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexeo Therapeutics, competition to find correlations between indicators driving Lexeo Therapeutics,'s intrinsic value. More Info.Lexeo Therapeutics, Common is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . At this time, Lexeo Therapeutics,'s Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexeo Therapeutics,'s earnings, one of the primary drivers of an investment's value.Lexeo Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexeo Therapeutics,'s direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexeo Therapeutics, could also be used in its relative valuation, which is a method of valuing Lexeo Therapeutics, by comparing valuation metrics of similar companies.Lexeo Therapeutics, is currently under evaluation in return on asset category among its peers.
Lexeo Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lexeo Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lexeo Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Lexeo Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 25.72 M | ||||
| Shares Outstanding | 33.06 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 91.48 % | ||||
| Number Of Shares Shorted | 2.31 M | ||||
| Price To Book | 1.24 X | ||||
| EBITDA | (66.67 M) | ||||
| Net Income | (66.39 M) | ||||
| Total Debt | 11.64 M | ||||
| Book Value Per Share | 4.99 X | ||||
| Cash Flow From Operations | (59.5 M) | ||||
| Short Ratio | 6.55 X | ||||
| Earnings Per Share | (12.53) X | ||||
| Target Price | 22.43 | ||||
| Number Of Employees | 69 | ||||
| Market Capitalization | 254.24 M | ||||
| Total Asset | 139.81 M | ||||
| Retained Earnings | (181.84 M) | ||||
| Working Capital | 107.06 M | ||||
| Net Asset | 139.81 M |
About Lexeo Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexeo Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexeo Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexeo Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 12.3 M | 12.9 M | |
| Cost Of Revenue | 2.1 M | 1.1 M | |
| Stock Based Compensation To Revenue | 2.45 | 2.57 | |
| Sales General And Administrative To Revenue | 16.52 | 17.34 | |
| Research And Ddevelopement To Revenue | 67.65 | 71.04 | |
| Capex To Revenue | 1.24 | 1.30 | |
| Revenue Per Share | 0.02 | 0.03 | |
| Ebit Per Revenue | (106.40) | (101.08) |
Pair Trading with Lexeo Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Lexeo Stock
| 0.66 | JNJ | Johnson Johnson | PairCorr |
| 0.77 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.7 | MRK | Merck Company Earnings Call This Week | PairCorr |
Moving against Lexeo Stock
| 0.54 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
| 0.52 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.46 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.41 | GILD | Gilead Sciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Lexeo Therapeutics, Piotroski F Score and Lexeo Therapeutics, Altman Z Score analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.